US009409892B2

(12) **United States Patent**
Ho et al.

(10) **Patent No.: US 9,409,892 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS**

(71) Applicant: **FIBROGEN, INC.**, San Francisco, CA (US)

(72) Inventors: **Wen-Bin Ho**, Los Altos, CA (US); **Hongda Zhao**, Dublin, CA (US); **Shaojiang Deng**, Foster City, CA (US); **Danny Ng**, Daly City, CA (US); **Lee R. Wright**, Redwood City, CA (US); **Min Wu**, Sunnyvale, CA (US); **Xiaoti Zhou**, Burlingame, CA (US); **Michael P. Arend**, Foster City, CA (US); **Lee A. Flippin**, Woodside, CA (US)

(73) Assignee: **FibroGen, Inc.**, San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/383,874**

(22) PCT Filed: **Mar. 8, 2013**

(86) PCT No.: **PCT/US2013/029912**

§ 371 (c)(1),
(2) Date: **Sep. 8, 2014**

(87) PCT Pub. No.: **WO2013/134660**

PCT Pub. Date: **Sep. 12, 2013**

(65) **Prior Publication Data**

US 2015/0038528 A1 Feb. 5, 2015

Related U.S. Application Data

(60) Provisional application No. 61/609,022, filed on Mar. 9, 2012.

(51) **Int. Cl.**

C07D 217/26	(2006.01)
C07D 401/12	(2006.01)
A61K 31/44	(2006.01)
A61K 31/47	(2006.01)
C07D 409/12	(2006.01)
C07D 401/04	(2006.01)
C07D 405/12	(2006.01)

(52) **U.S. Cl.**
CPC ***C07D 409/12*** (2013.01); ***C07D 217/26*** (2013.01); ***C07D 401/04*** (2013.01); ***C07D 401/12*** (2013.01); ***C07D 405/12*** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,989,704	A	11/1976	Houlihan et al.
4,036,964	A	7/1977	Buckle et al.
4,260,611	A	4/1981	Bartmann et al.
4,559,403	A	12/1985	Bruderer et al.
4,584,379	A	4/1986	Wagner
4,673,682	A	6/1987	Konz et al.
4,822,800	A	4/1989	Faltico et al.
4,952,588	A	8/1990	Glamkowski et al.
4,966,906	A	10/1990	Glamkowski et al.
5,620,995	A	4/1997	Weidmann et al.
5,658,933	A	8/1997	Weidmann et al.
5,719,164	A	2/1998	Weidmann et al.
5,726,305	A	3/1998	Weidmann et al.
6,093,730	A	7/2000	Weidmann et al.
6,319,931	B1	11/2001	Kroemer et al.
6,358,973	B1	3/2002	Napoletano et al.
6,358,976	B1	3/2002	Wityak et al.
6,369,053	B1	4/2002	Yuan et al.
6,762,318	B2	7/2004	Kodra et al.
6,777,425	B2	8/2004	Burli et al.
6,903,114	B2	6/2005	Backstrom et al.
7,208,601	B2	4/2007	Mjalli et al.
7,323,475	B2	1/2008	Arend et al.
7,629,357	B2	12/2009	Arend et al.
7,696,223	B2	4/2010	Deng et al.
7,863,292	B2	1/2011	Arend et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2134866	5/1995
EP	0650960	5/1995

(Continued)

OTHER PUBLICATIONS

International Search Report and Written Opinion for PCT/US2013/029912 dated Mar. 8, 2013, 3 pages.

(Continued)

Primary Examiner — Zinna Northington Davis

(74) *Attorney, Agent, or Firm* — Leanne C. Price; Sheppard Mullin Richter & Hampton LLP

(57) **ABSTRACT**

The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.

(I)



30 Claims, No Drawings